RA
AXSM icon

Royce & Associates’s Axsome Therapeutics AXSM Stock Holding History

Royce & Associates’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.3M Sell
91,041
-2,976
-3% -$645K 0.18% 187
2026
Q1 		$15.9M Hold
94,017
– – 0.16% 202
2025
Q4 		$17.2M Buy
94,017
+37,981
+68% +$5.3M 0.17% 180
2025
Q3 		$6.81M Buy
56,036
+30,279
+118% +$3.41M 0.07% 402
2025
Q2 		$2.69M Sell
25,757
-4,500
-15% -$476K 0.03% 559
2025
Q1 		$3.53M Sell
30,257
-6,743
-18% -$768K 0.04% 498
2024
Q4 		$3.13M Buy
37,000
+14,500
+64% +$1.33M 0.03% 559
2024
Q3 		$2.02M Buy
22,500
+9,500
+73% +$829K 0.02% 620
2024
Q2 		$1.05M Hold
13,000
– – 0.01% 715
2024
Q1 		$1.04M Buy
+13,000
New +$1.09M 0.01% 721
2021
Q3 		– Sell
-20,300
Closed -$1.37M – 985
2021
Q2 		$1.37M Sell
20,300
-5,400
-21% -$324K 0.01% 813
2021
Q1 		$1.46M Hold
25,700
– – 0.01% 803
2020
Q4 		$2.09M Hold
25,700
– – 0.02% 715
2020
Q3 		$1.83M Hold
25,700
– – 0.02% 694
2020
Q2 		$2.12M Sell
25,700
-14,400
-36% -$1.11M 0.02% 656
2020
Q1 		$2.36M Sell
40,100
-20,000
-33% -$1.63M 0.03% 559
2019
Q4 		$6.21M Sell
60,100
-44,600
-43% -$1.8M 0.06% 436
2019
Q3 		$2.12M Sell
104,700
-10,000
-9% -$257K 0.02% 696
2019
Q2 		$2.95M Sell
114,700
-67,700
-37% -$1.36M 0.03% 624
2019
Q1 		$2.6M Sell
182,400
-150,000
-45% -$1.39M 0.02% 665
2018
Q4 		$937K Hold
332,400
– – 0.01% 871
2018
Q3 		$1.15M Sell
332,400
-556,000
-63% -$1.65M 0.01% 899
2018
Q2 		$2.84M Sell
888,400
-67,600
-7% -$209K 0.02% 751
2018
Q1 		$2.34M Buy
956,000
+75,000
+9% +$225K 0.02% 807
2017
Q4 		$4.93M Hold
881,000
– – 0.03% 590
2017
Q3 		$4.89M Hold
881,000
– – 0.03% 576
2017
Q2 		$4.85M Hold
881,000
– – 0.03% 597
2017
Q1 		$3.44M Buy
+881,000
New +$4.21M 0.02% 705

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royce & Associates's AXSM Position: Q2 2026 in Review

Royce & Associates reduced its Axsome Therapeutics (AXSM) stake by 3.2% in Q2 2026, selling an estimated $645K and leaving 91,041 shares worth $22.3M. The position accounts for 0.18% of the portfolio, ranked #187.

Royce & Associates first reported a position in AXSM in Q1 2017 and has held it in 28 quarters since. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Royce & Associates held 91,041 shares of Axsome Therapeutics worth $22.3M as of Q2 2026.
  • Royce & Associates sold 2,976 Axsome Therapeutics shares in Q2 2026, an estimated $645K.
  • Axsome Therapeutics made up 0.18% of Royce & Associates's portfolio in Q2 2026, its #187 holding.
  • Royce & Associates first reported a position in Axsome Therapeutics in Q1 2017 and has held it in 28 quarters since.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.